[
  {
    "ts": null,
    "headline": "Biogen Inc. (NASDAQ:BIIB) is largely controlled by institutional shareholders who own 90% of the company",
    "summary": "Key Insights Significantly high institutional ownership implies Biogen's stock price is sensitive to their trading...",
    "url": "https://finnhub.io/api/news?id=10267bcd617e23ba8d8bbe1750438e8430eb148f8aec20cc5072b67f5cf345c9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746034280,
      "headline": "Biogen Inc. (NASDAQ:BIIB) is largely controlled by institutional shareholders who own 90% of the company",
      "id": 134166791,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Key Insights Significantly high institutional ownership implies Biogen's stock price is sensitive to their trading...",
      "url": "https://finnhub.io/api/news?id=10267bcd617e23ba8d8bbe1750438e8430eb148f8aec20cc5072b67f5cf345c9"
    }
  },
  {
    "ts": null,
    "headline": "Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y",
    "summary": "SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.",
    "url": "https://finnhub.io/api/news?id=e37a5b855ceab8b0bc7454b0a520108fcd17bc2ed8f44e5190108c2617256531",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746029820,
      "headline": "Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y",
      "id": 134166792,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.",
      "url": "https://finnhub.io/api/news?id=e37a5b855ceab8b0bc7454b0a520108fcd17bc2ed8f44e5190108c2617256531"
    }
  },
  {
    "ts": null,
    "headline": "Unveiling Biogen (BIIB) Q1 Outlook: Wall Street Estimates for Key Metrics",
    "summary": "Get a deeper insight into the potential performance of Biogen (BIIB) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.",
    "url": "https://finnhub.io/api/news?id=aeb75217d6d17bee63569b6d529993080e2e632932c4746fe0f7cd70a6817ca0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746018919,
      "headline": "Unveiling Biogen (BIIB) Q1 Outlook: Wall Street Estimates for Key Metrics",
      "id": 134166793,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Get a deeper insight into the potential performance of Biogen (BIIB) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.",
      "url": "https://finnhub.io/api/news?id=aeb75217d6d17bee63569b6d529993080e2e632932c4746fe0f7cd70a6817ca0"
    }
  },
  {
    "ts": null,
    "headline": "Q1 2025 SAGE Therapeutics Inc Earnings Call",
    "summary": "Q1 2025 SAGE Therapeutics Inc Earnings Call",
    "url": "https://finnhub.io/api/news?id=df37a3bdcc30d38ac0ebb848a6b12e32f5fea438f95007e17a3b8b7444b63a8f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746014711,
      "headline": "Q1 2025 SAGE Therapeutics Inc Earnings Call",
      "id": 134166794,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Q1 2025 SAGE Therapeutics Inc Earnings Call",
      "url": "https://finnhub.io/api/news?id=df37a3bdcc30d38ac0ebb848a6b12e32f5fea438f95007e17a3b8b7444b63a8f"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Earnings: What To Look For From BIIB",
    "summary": "Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know.",
    "url": "https://finnhub.io/api/news?id=5f9be45e02582d49977c427f67ae9a3948f5d601fc8a1a3cbba14ccc10e97425",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745997269,
      "headline": "Biogen Earnings: What To Look For From BIIB",
      "id": 134141616,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know.",
      "url": "https://finnhub.io/api/news?id=5f9be45e02582d49977c427f67ae9a3948f5d601fc8a1a3cbba14ccc10e97425"
    }
  }
]